Ovarian Cancer Newswire

Comprehensive Real-Time News Feed for Ovarian Cancer.

Results 1 - 20 of 1,634 in Ovarian Cancer

  1. Critical Outcome Technologies Reports Year-End Financial and Operating ResultsRead the original story

    2 hrs ago | Hispanic Business

    ... clinical trial; and, -- Submitting an application for Orphan Drug Designation for COTI-2 in the treatment of ovarian cancer. "In fiscal 2014, we made substantial progress with respect to three core initiatives focused on future revenue generation," ...

    Comment?

  2. Parasite In Cat Poop Could One Day Treat CancerRead the original story w/Photo

    3 hrs ago | Switched

    ... Toxoplasma parasite, Bzik and his colleagues treated mice that had the skin cancer melanoma and mice that had ovarian cancer. In recent studies , they showed the treatment shrank the tumor and increased the mice's chances of survival. However, much ...

    Comment?

  3. Intersect ENT prices its IPO low as biotech offerings start to wobbleRead the original story w/Photo

    4 hrs ago | Business Journal

    ... Wednesday that the company is postponing its offering because it received data from preclinical work on an ovarian cancer drug. The company opted to delay the offering, Thomson Reuters reported, to allow it time to disclose the information to ...

    Comment?

  4. This root vegetable helps you fight diseasesRead the original story

    5 hrs ago | Mydigitalfc.com

    ... which is a considered a precursor to colon cancer. A very important use of ginger is in reversing ovarian cancer. A study found that exposing ovarian cancer cells to a solution of ginger powder resulted in their death in every single test! How cool ...

    Comment?

  5. Ovarian Cancer Therapeutics to 2020: Industry Analysis, Size, Share, Growth, Trends and ForecastRead the original story

    7 hrs ago | SBWire

    Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free Survival and Targeted Therapies".

    Comment?

  6. Nasal stent developer Intersect ENT prices IPO at bottom of rangeRead the original story w/Photo

    9 hrs ago | Business Journal

    ... Wednesday that the company is postponing its offering because it received data from preclinical work on an ovarian cancer drug and needed to disclose that information to investors. The offering of 5.75 million shares was likely to price toward the ...

    Comment?

  7. Predictive biomarkers for cancer therapy with PARP inhibitorsRead the original story

    16 hrs ago | Oncogene

    ... break; DSBR, double-strand break repair; EGBFr, epidermal growth factor receptor; EOC, epithelial ovarian cancer; GI, gastro-intestinal; HDAC, histone deacetylase; HzR, hazard ratio; HR, homologous recombination; HRD, homologous recombination ...

    Comment?

  8. IPO Preview: Atara BiotherapeuticsRead the original story

    17 hrs ago | Seeking Alpha

    ... ATRA's second product candidate is STM 434, and ATRA expects to enter a Phase 1 clinical study of STM 434 for ovarian cancer and other solid tumors in the second half of 2014. ATRA has five additional molecules in preclinical development. ATRA ...

    Comment?

  9. Researchers from Mayo Clinic Report Findings in Nanoparticles...Read the original story

    19 hrs ago | Hispanic Business

    ... toxicity." For more information on this research see: Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. , Cancer, Emerging Technologies, Nanoparticle, Nanoparticles, Nanotechnology, Oncology. Our reports ...

    Comment?

  10. Make a Homemade Sriracha BBQ SauceRead the original story w/Photo

    19 hrs ago | San Fernando Sun

    ... A Four day Course for the higher degree students. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer. Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has ...

    Comment?

  11. Pinay cancer survivor bikes across US to help homelessRead the original story w/Photo

    22 hrs ago | ABS-CBN News

    ... bars has been Monica Busby's view for the six weeks. By the end of her 2-month trip which began in June, the ovarian cancer survivor will embark on a 3,600-mile cross-country bike ride from New Jersey to Oregon, helping the homeless through the ...

    Comment?

  12. Aduro BioTech Names Industry Veteran and Academic Leader, Gerald Chan, DSc to its Board of DirectorsRead the original story

    Yesterday | Hispanic Business

    ... mesothelioma and high-grade glioma and its immunotherapies are in development in non-small cell lung cancer, ovarian cancer and prostate cancer. The company is also developing clinical candidates using novel small molecules that activate the ...

    Comment?

  13. Global Drug Delivery in Cancer Report 2014-Technologies, Markets and CompaniesRead the original story

    Yesterday | Hispanic Business

    ... one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them ...

    Comment?

  14. 'Planet Lori' art camp is Aug. 25-29 at BBACRead the original story w/Photo

    Yesterday | ClickOnDetroit

    ... Haber Buckfire, a young mother and talented artist from Bloomfield Hills who lost her five-year battle with ovarian cancer in July 2010 at age 41, is holding the Planet Lori art camp this summer from August 25-29th at Birmingham Bloomfield Art ...

    Comment?

  15. Cat Poop Goes Under the Microscope for Cancer ResearchRead the original story w/Photo

    Yesterday | Live Science

    ... Toxoplasma parasite, Bzik and his colleagues treated mice that had the skin cancer melanoma and mice that had ovarian cancer. In recent studies , they showed the treatment shrank the tumor and increased the mice's chances of survival. However, much ...

    Comment?

  16. Endocyte Shareholder Alert: Former SEC Attorney Willie Briscoe and...Read the original story

    Yesterday | Business Wire

    ... actually wholly ineffective in slowing down or otherwise aiding in the treatment of PROC (platinum-resistant ovarian cancer); b) The Data and Safety Monitory Board ("DSMB") would reveal Vintafolide's ineffectiveness and likely recommend a halt to ...

    Comment?

  17. Too Early To Tell For Atara Biotherapeutics IPORead the original story

    Yesterday | Seeking Alpha

    ... useful anti-inflammatory properties. ATRA's second product candidate, known as STM 434, is designed to treat ovarian cancer and other solid tumors. STM 434 binds to Activin, a protein associated with ovarian cancer as well as larger tumors and ...

    Comment?

  18. Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland.Read the original story

    Yesterday | CiteULike

    ... three observed compared with 12 expected cases) after two purchases. The standardized incidence ratio for ovarian cancer was 0.60 (95% CI 0.45-0.76; 59 observed compared with 99 expected cases), for pancreatic cancer 0.50 (95% CI 0.28-0.81; 15 ...

    Comment?

  19. Celsion's EGEN Acquisition Brings Immunotherapy And RNA Therapeutics To Its Cancer PlatformRead the original story w/Photo

    Tuesday | Seeking Alpha

    ... to deliver EGEN-001 overcomes this obstacle, as shown in clinical trials. EGEN-001 was first tested alone in ovarian cancer, a market estimated to grow to $1.6 billion over the next eight years. Ovarian cancer is usually advanced at the time of ...

    Comment?

  20. FDA Grants Priority Review to Bevacizumab (Avastin) for Ovarian CancerRead the original story

    Tuesday | P&T Community

    The FDA has accepted a supplemental biologics license application for bevacizumab plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer, and has granted the therapy priority review.

    Comment?